Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 1, 1998, Pages 64-78

  Montré, France ^a   Pousset, Françoise ^b   Comets, Emmanuelle ^b   Plaud, Benoît ^b   Diquet, Bertrand ^b   Montalescot, Gilles ^b   Ankri, Annick ^b   Mallet, Alain ^b   Lechat, Philippe ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FLUINDIONE; PROTHROMBIN; PROTHROMBIN COMPLEX; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEART ATRIUM FIBRILLATION; HEART DILATATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTHROMBIN TIME; STATISTICS; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; MIDDLE AGED; PHENINDIONE;

EID: 0031894453     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90122-9     Document Type: Article

References (27)

1. Tillement JP, Thebault JJ, Mattei C, d'Athis P, Blatrix C. Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man. Eur J Clin Pharmacol 1975;8:271-5.
2. Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994;56:286-94.
3. Tillement JP, Zini R, Mattei C, Singlas E. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol 1973;6:15-8.
4. Laupacis A, Albers G, Dalen JE, Dunn MI, Feinberg W, Jacobson AK. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S-9S.
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
6. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
7. Hylek EM, Skates SJ, Sheelan MA, Singer DI. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
8. Hirsh J, Dalen JE, Deykin D, Poller L, Brussey HI. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108:231S-46S.
9. Breckenridge AM. Interindividual differences in the response to oral anticoagulant. Drugs 1977;14:367-75.
10. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986;11:483-504.
11. Bjornsson TD, Terzic A. Pharmacokinetics and pharmacodynamics of anticoagulant drugs. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier; 1992. p. 303-11.
12. Palareti G, Legnani C. Warfarin withdrawal, pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300-13.
13. Roncato M, Billaud-Mesguich E, Fiessinger JN, Vitoux JF, Aiach M, Alexandre JM. Traitement anticoagulant par la fluindione. Relation entre la décroissance des facteurs dépendant de la vitamine K et de la fluindionémie. Thérapie 1986;41:203-6.
14. Cazaux V, Gauthier B, Lefebvre D, Tredez J, Nguyen F, Cambus JP, et al. Predicting daily maintenance dose of fluindione, an oral anticoagulant drug. Thromb Haemost 1996;75:731-3.
15. Jusko WJ, Ko HC. Physiologic indirect-response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
16. Pitsiu M, Parker EM, Aarons L, Rowland M. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 1993;1:151-7.
17. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986;73:645-56.
18. Mentré F, Mallet A. Handling covariates in population pharmacokinetics. Int J Biomed Comput 1994; 36:25-33.
19. Jerling M, Merlé Y Mentré F, Mallet A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6: an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38:453-62.
20. Mentré F, Ebelin ME. Validation in population pharmacokinetic/pharmacodynamic analyses: review of proposed approaches. In: Aarons L, Balnat LP, Danhof M, Gex-Fabry M, Gundert-Remy UA, Karlsson M, et al, editors. The population approach: measuring and managing variability in response, concentration and dose. Bruxelles: European Commission; 1997 p. 147-60.
21. Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985;13:213-27.
22. Murray B, Coleman R, McWaters D, Ludden T, Mungall D. Pharmacodynamics of warfarin at steady state. Ther Drug Monit 1987;9:1-5.
23. Chan E, Aarons L, Serllin M, Breckenridge A, Rowland M. Interrelationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol 1987; 24:621-5.
24. Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1968;10:22-35.
25. Sheiner LB. Computer-aided long-term anticoagulation therapy. Comput Biomed Res 1969;2:507-18.
26. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. London: Chapman & Hall; 1995.
27. Verotta D, Sheiner LB. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm 1995;23:1-4.